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Life-long immunity is central to the survival of 
the host. This immunity is engendered by the 
persistence of memory T cells, memory B cells 
(BMEM), and long-lived BM plasma cells (PCs; 
Amanna et al., 2007; Dörner and Radbruch, 
2007). Long-lasting B cell–mediated immunity 
has been referred to as serological memory 
(Traggiai et al., 2003) and can be sustained by 
recurrent antigen exposure. In the absence of 
periodic exposure to antigen, it is thought that 
the production of inflammatory signals to un-
related antigens serve as mediators sustaining se-
rologic memory through activation of BMEM in 
a noncognate manner. The in vitro and in vivo 
response profiles of antigen-specific BMEM to 
cognate antigen and “nonspecific” or bystander 
inflammatory mediators are analyzed herein to 
critically evaluate the mechanisms underlying 
the maintenance of serological memory.
BMEM and long-lived PCs are the products 
of the germinal center (GC) reaction and ex-
press somatically hypermutated (SHM) immuno-
globulin receptors of the switched isotypes 
(MacLennan, 1994; McHeyzer-Williams and 
Ahmed, 1999). After BMEM exit from the GC 
reaction, they colonize the splenic marginal 
zones (MZs) and the B cell follicles, where they 
reside in a quiescent state for months or, likely, 
years (Liu et al., 1988, 1991; Schittek and 
Rajewsky, 1990; Anderson et al., 2007). Upon 
rechallenge with cognate antigen, histological 
studies in rats observed that BMEM egress to-
ward the T cell–rich periarteriolar lymphocytic 
sheath and, upon receiving T cell help, prolif-
erate and differentiate into plasmablasts (PBs) 
situated in both the periarteriolar lymphocytic 
sheath and in the splenic red pulp (Liu et al., 
1991). Kinetic studies indicate that the genera-
tion of this response is rapid and peaks 4-5 d 
after secondary antigen encounter (Liu et al., 
1991; McHeyzer-Williams et al., 2000; Minges 
Wols et al., 2007). The PB response dissipates 
shortly after its initiation, with a subset of PBs 
further differentiating into long-lived PCs resi-
dent in the BM (Liu et al., 1991; Manz et al., 
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The hypothesis that bystander inflammatory signals promote memory B cell (BMEM) self-
renewal and differentiation in an antigen-independent manner is critically evaluated 
herein. To comprehensively address this hypothesis, a detailed analysis is presented examin-
ing the response profiles of B-2 lineage B220+IgG+ BMEM toward cognate protein antigen in 
comparison to bystander inflammatory signals. After in vivo antigen encounter, quiescent 
BMEM clonally expand. Surprisingly, proliferating BMEM do not acquire germinal center (GC) 
B cell markers before generating daughter BMEM and differentiating into plasma cells or 
form structurally identifiable GCs. In striking contrast to cognate antigen, inflammatory 
stimuli, including Toll-like receptor agonists or bystander T cell activation, fail to induce 
even low levels of BMEM proliferation or differentiation in vivo. Under the extreme condi-
tions of adjuvanted protein vaccination or acute viral infection, no detectable bystander 
proliferation or differentiation of BMEM occurred. The absence of a BMEM response to non-
specific inflammatory signals clearly shows that BMEM proliferation and differentiation is a 
process tightly controlled by the availability of cognate antigen.
© 2009 Benson et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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agonists, polyclonal T cell activation, protein vaccination, 
and even acute vaccinia virus infection, BMEM neither clon-
ally expand nor differentiate into ASCs, and thus appear ig-
norant to overt bystander inflammatory signals.
RESULTS
Antigen-specific and polyclonal BMEM cells are responsive  
to TLR agonists in vitro and display an enhanced capacity  
to differentiate into ASCs when compared with NF B cells
A comprehensive analysis of BMEM responsiveness to antigen 
and bystander inflammatory stimuli was undertaken both in 
vitro and in vivo. The term “bystander” is defined herein as 
stimuli acting on BMEM independent of BCR engagement. 
In these studies, we tracked BMEM specific for the thymus- 
dependent protein antigen R-phycoerythrin (PE), as immu-
nization of BALB/c mice with this fluorophore elicits a 
detectable population of PE-binding BMEM at a high resolu-
tion (referred to as PE-BMEM; Hayakawa et al., 1987). After 
immunization with PE adsorbed to alum i.p., PE-BMEM are 
readily detectable in the spleen at 0.01–0.05% of total spleno-
cytes beginning 21 d after immunization, with this popula-
tion still present 60 d after priming (Fig. S1; Hayakawa et al., 
1987; Schittek and Rajewsky, 1990; Benson et al., 2008). In 
nonimmunized mice, a minute naive PE-binding population 
is observed at a 10-fold lower frequency (Fig. S1). The PE-
BMEM in immunized mice are predominantly B220+PE+CD3
8+IgDIgG1+CD80hi and express a phenotype consistent 
with long-lived affinity-matured BMEM (Fig. S1; Anderson 
et al., 2007). In all experiments (unless indicated otherwise), 
PE-BMEM from PE/alum-immunized mice were analyzed 
between days 60 and 90 after primary immunization.
The response of PE-BMEM to inflammatory stimuli was 
first analyzed by examining the response profile of BMEM to a 
panel of TLR agonists in vitro. We also included two other 
sources of BMEM in these in vitro analyses to first ensure that 
the results were reproducible in multiple systems and to test 
whether BMEM activation occurs in the absence of BCR 
cross-linking. The second system used BMEM raised against 
and specific for the hapten 4-hydroxy-3-nitrophenylacetyl 
(NP), with this system having been previously characterized 
(McHeyzer-Williams et al., 1991; Lalor et al., 1992). The 
third system used BMEM from a transgenic mouse in which 
the polyclonal BMEM population is readily identified. This lat-
ter source allowed for the isolation of BMEM without the need 
for BCR engagement by antigen, as when PE-BMEM and 
NP-BMEM are purified using antigen binding to denote speci-
ficity, cross-linking the BCR is inevitable.
PE-BMEM cells. From PE-immunized mice, PE-BMEM 
were first enriched by negative selection, and then elec-
tronically sorted based on a B220+PE+dumpCD38+ phe-
notype, with post-sort analysis indicating high levels of 
purity (Fig. S2 A).
NP-specific BMEM cells. NP-BMEM were generated in a 
transgenic mouse strain where Cre recombinase was inserted 
1997; McHeyzer-Williams et al., 2006). Shortly after re-
call, BMEM cells are once again present in their initial ana-
tomical positions (Liu et al., 1991). Despite numerous 
studies carefully mapping out the events of the primary 
humoral immune response toward protein antigens (Jacob 
et al., 1991; MacLennan, 1994; Allen et al., 2007), rela-
tively little is known about the events occurring during a 
secondary humoral immune response, including whether 
antigen reencounter results in the expression of GC mark-
ers by antigen-responding BMEM and/or if BMEM form GC 
structures en route to differentiating into PCs (Liu et al., 
1991; MacLennan, 1994; McHeyzer-Williams et al., 2006). 
As the fate and behavior of antigen-activated BMEM is criti-
cal to our understanding of BMEM self-renewal, included in 
this study is a detailed analysis of the in vivo response of 
BMEM toward cognate antigen.
The mechanisms mediating the survival of BMEM are un-
known. Although BMEM require phospholipase C  signaling 
through the B cell receptor (BCR) for survival, it is clear that 
the BMEM BCR need not be permanently engaged with anti-
gen, as BMEM do not require the presence of persisting anti-
gen or antigen complexes to survive (Maruyama et al., 2000; 
Anderson et al., 2006; Hikida et al., 2009). It is apparent that 
BMEM occupy a survival niche independent from other B-2 
lineage cell subsets, as, unlike all other mature cells of the B-2 
lineage, they do not require BAFF and APRIL survival sig-
nals (Benson et al., 2008; Scholz et al., 2008). At the level of 
the organism, it is thought that humoral memory as a whole 
is sustained by the stem cell–like qualities of BMEM, with this 
cell type undergoing low levels of self-renewal and replenish-
ment of the long-lived PC pool over the lifetime of the or-
ganism (Traggiai et al., 2003). To sustain serological memory 
in the absence of cognate antigen, it has been hypothesized 
that quiescent BMEM are periodically activated by Toll-like 
receptor (TLR) agonists or bystander T cell help to undergo 
self-renewal events and differentiate into antibody-secreting 
cells (ASCs) such as PBs and PCs in an antigen-independent 
manner (Bernasconi et al., 2002). A crucial element of this 
theory was the prediction that inflammatory stimuli associ-
ated with adaptive immune responses drive the activation of 
BMEM in an antigen-independent (i.e., nonspecific) manner 
in vivo (Bernasconi et al., 2002, 2003; Traggiai et al., 2003). 
Whether BMEM are indeed reactive to bystander inflamma-
tory stimuli in vivo has not yet been tested from the vantage 
point of BMEM.
In this work, we detail the ability of BMEM to undergo 
self-renewal and to differentiate into ASCs in response to 
both antigen-dependent and bystander inflammatory stimuli. 
In studying these events, we also demonstrate that during 
clonal expansion in response to cognate antigen, BMEM do 
not express a GC B cell phenotype, and that GC structures 
are not generated en route to differentiating into ASCs. We 
find that BMEM are responsive to inflammatory stimuli in vi-
tro, with activated BMEM displaying a markedly enhanced ca-
pacity to differentiate into ASCs when compared with naive 
follicular (NF) B cells. However, in vivo, in response to TLR 
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and NF B responded poorly or did not respond to agonists 
for TLR2, TLR3, and TLR5 (unpublished data). For each 
TLR agonist that NF B cells or poly-BMEM responded to, 
BMEM generated a sizable population of B220intCD138+ cells, 
whereas NF B cells maintained a B220+CD138 phenotype 
(Fig. 1 H). NF B cells also proliferated to a greater degree 
than BMEM (Fig. 1 I). Finally, it was observed that while en-
gagement of CD40 drove proliferation of both BMEM and NF 
B cells, BMEM did not differentiate into B220intCD138+ cells 
(Fig. 1, H–I). Collectively, these data show that BMEM are 
sensitive to multiple TLR agonists in vitro and do not re-
quire BCR cross-linking to become activated and differenti-
ate into ASCs. Furthermore, upon activation, BMEM have an 
enhanced intrinsic capacity to differentiate into CD138+ 
ASCs compared with NF B cells. Lastly, CD40 signaling ap-
pears to drive BMEM proliferation, but to block differentiation 
in vitro.
BMEM cells undergo rapid clonal expansion  
and differentiation into IgG+ ASCs in response  
to soluble antigen
Having established that BMEM are responsive to bystander 
stimuli in vitro, we used the PE-antigen system to compare 
BMEM responsiveness toward cognate antigen versus bystander 
inflammation in vivo. We first performed a detailed analysis 
of the secondary humoral immune response to soluble PE 
(sPE) to define the behavior and kinetics of BMEM activation 
in vivo. Unlike naive hosts, it is well-established that previ-
ously immunized mice are responsive to low-doses of antigen 
in the absence of adjuvant (McHeyzer-Williams et al., 2006). 
This heightened responsiveness results from the combined 
presence of antigen-reactive BMEM and CD4+ memory T 
cells. In concordance with this, we observed that injection of 
naive mice with 1 µg sPE (or 10 µg; not depicted) failed to 
elicit PE-ASCs (Fig. 2, A and B), whereas PE-immunized 
mice produced high numbers of IgG+ PE-ASCs. A robust 
IgM ASC response was only elicited when naive or PE-im-
munized mice were injected with 1 µg of sPE along with the 
TLR9 agonist CpG ODN 1826 (CpG; Fig. 2 A). Thus, the 
IgG+ PE-specific humoral response generated after sPE injec-
tion is likely the direct consequence of BMEM activation. 
These data demonstrate that a low level of sPE given in the 
absence of adjuvant is capable of activating PE-BMEM to dif-
ferentiate into IgG+ ASCs.
The in vivo proliferation of PE-BMEM was measured by 
flow cytofluorimetric analysis of BrdU incorporation. PE-
 immunized mice were injected with sPE, and a 5-d BrdU pulse 
was performed starting on the day of sPE injection, followed 
by a chase period. BrdU incorporation by BMEM was quantified 
at various times during and after the pulse period. After preen-
richment, PE-BMEM were detected by excluding CD4/CD8/
IgD/IgM+ cells via a dump gate and gating them on B220+PE+ 
cells, with these cells analyzed for BrdU incorporation (Fig. S3 A). 
PE-immunized mice receiving BrdU, but no antigen, and 
immunized mice receiving neither antigen nor BrdU were 
included as negative controls (Fig. 2 C). 2 d after sPE 
in the C1 locus, with this strain crossed with the Rosa26-
EYFP reporter mouse (Casola et al., 2006). In this mouse, 
every post-GC B cell expresses YFP, with this strain afford-
ing the opportunity to track post-GC B cell subsets by YFP 
expression (Casola et al., 2006). Immunization of C1-cre/
Rosa26-EYFP mice with NP-keyhole limpet hemocyanin 
(KLH)/alum lead to the generation of NP-BMEM (Fig. S2 B; 
Casola et al., 2006). After negative enrichment, NP-BMEM 
were defined as B220+ NIP+IgG1/YFP+dumpCD38+, with 
post-sort analysis indicating purity (Fig. S2 B).
Polyclonal BMEM cells. Polyclonal BMEM can be clearly 
enumerated in C1-cre/Rosa26-EYFP mice through ex-
pression of YFP, loss of IgD and IgM, and expression of other 
BMEM markers. NP-immunized C1-cre/Rosa26-EYFP 
mice were negatively enriched for BMEM with polyclonal 
BMEM defined as B220+IgG1/YFP+CD38+dumpCD80+ 
and sorted to purity (Fig. 1 C).
NF B cells. In parallel, NF B cells were defined as 
B220+CD23+IgD+CD38+ and were additionally sorted 
(Fig. S2 C).
The response of PE-BMEM, NP-BMEM, poly-BMEM, and 
NF B cells to TLR agonists after 3 d of in vitro culture was 
analyzed (Fig. 1). PE-BMEM and corresponding NF B cells 
and IL-4–only controls were stained with CFSE, whereas 
NP-BMEM and poly-BMEM with NF B cells and IL-4 only 
controls were stained with DDAO to track proliferation. Af-
ter culture with the TLR4 agonist LPS, cells were analyzed 
for surface expression of B220 and CD138. The culture of 
all NF and BMEM with IL-4 resulted in a uniform B220+ pop-
ulation after 3 d (unpublished data). Upon culture of NF B 
cells and BMEM with LPS, NF B cells remained primarily 
B220+CD138, whereas all three sources of BMEM generated 
a B220intCD138+ population of cells (21–30% of total) rep-
resenting the phenotype of a ASC (Fig. 1, A and D). The 
ASCs derived from the three sources of BMEM were of the 
IgG isotype and, with the ASCs generated from PE-BMEM 
and NP-BMEM, specific for either PE or NP, respectively 
(Fig. 1 G and not depicted). NF B cells generated a high fre-
quency of IgM+ ASCs (Fig. 1 G). The overall degree of pro-
liferation by the three sources of BMEM was moderately less 
than NF B cells, although proliferation did occur, as indi-
cated by comparison to the IL-4–only cultured cells (Fig. 1, 
B and E). The population of B220intCD138+ cells generated 
from poly-BMEM arose in the daughter peaks, showing that 
BMEM undergo cell division while differentiating into 
B220intCD138+ cells (Fig. 1 F).
The response of poly-BMEM and NF B cells was analyzed 
to either Pam3CSK4 (TLR1/2 agonist), heat-killed Listeria 
monocytogenes (TLR2 agonist), poly(I:C) (TLR3 agonist), 
LPS (TLR4 agonist), flagellin from Salmonella typhimurium 
(TLR5 agonist), FSL-1 (TLR6 agonist), S-27609 (TLR7 ag-
onist), ODN 1826 (TLR9 agonist), and IL-4. Both NF B 
cells and poly-BMEM were responsive to agonists for TLR1/2, 
TLR4, TLR6, TLR7, and TLR9 (Fig. 1 I). Both poly-BMEM 
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Figure 1. Antigen-specific and polyclonal BMEM cells are responsive to TLR agonists in vitro and display an enhanced capacity to differenti-
ate into ASCs compared with NF B cells. NP-BMEM and PE-BMEM were sorted by FACS, along with NF B cells. NP-BMEM and NF B cells were stained with 
DDAO and PE-BMEM, and NF B cells were stained with CFSE. Cells were cultured for 3 d with 10 µg/ml LPS, whereupon the cell surface phenotype was 
analyzed for the expression of B220 and CD138 (A) or DDAO or CFSE (B), with the percentage of B220+CD138+ cells depicted (A). (B) Filled histograms,  
B cells + IL-4; gray lines, BMEM; black lines, NF B cells. To analyze the reactivity of BMEM to TLR agonists in the absence of BCR cross-linking, poly-BMEM were 
used. Spleens from NP-KLH–immunized C1-cre/ROSA-YFP mice were enriched for BMEM, with poly-BMEM present in the remaining population sorted by 
the phenotype B220+IgG1/YFP+CD38+DumpCD80+. Dump gates, CD43+IgD+IgM+ cells (C). Both poly-BMEM and NF B cells were labeled with DDAO and 
cultured for 3 d in the presence of either 10 µg/ml LPS or 5 µM CpG, whereupon the cell surface phenotype was analyzed for the expression of B220 and 
CD138 (D) and DDAO dye dilution (E). (E) Gray lines, B cells + IL-4; black lines, NF or poly-BMEM as indicated. Proliferation as a function of CD138 expres-
sion is shown, with the percentage of cells that have diluted DDAO and are expressing CD138 shown (F). The ability of cells derived from either NF B cells 
(open bars) or BMEM (filled bars) after 3 d of LPS culture to secrete antibody of the IgM, IgG1, IgG2a, IgG2b, IgG3, IgE, and IgA isotypes was analyzed by 
ELISpot analysis (F). The response profiles of poly-BMEM and NF B cells to a panel of TLR agonists was examined after 3 d of culture with the indicated 
agonist. The agonists used, their abbreviations, the receptors for which they are specific for, and the concentrations used are as follows: Pam3CSK4 (P3C), 
TLR1/2, 1 µg/ml; LPS (LPS), TLR4, 10 µg/ml; FSL-1 (FSL1), TLR6/2, 1 µg/ml; S-27609 (609), TLR7, 1 µg/ml; CpG ODN 1826 (CpG), TLR9, 5 µM, CD40 
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The observation that 50% of BMEM respond to sPE as 
indicated by BrdU incorporation (Fig. 2 C and Fig. S3 A) led 
us to question whether either the antigen dose or the absence 
of adjuvant during antigen administration was limiting the 
frequency of responding BMEM. To test this, we varied the 
amount of sPE injected or added CpG during antigen rechal-
lenge, with BrdU administration concurrently initiated. 
When analyzed 3 d later, it was observed that the dose of an-
tigen positively correlated with the percentage of proliferat-
ing BMEM (Fig. 2 G and Fig. S3 B). The addition of CpG had 
no further impact on the frequency of responding PE-BMEM 
(Fig. 2 G and Fig. S3 C). However, the addition of CpG to 
sPE modestly increased the number of splenic IgG+ PE-ASCs 
elicited after 3 d when compared with sPE alone (Fig. 2 B). 
In sum, these data indicate that antigen can be a limiting fac-
tor in dictating the frequency of responding BMEM. Notably, 
TLR9 agonists failed to enhance the frequency of activated 
BMEM. This point indicates that CpGs alone may not play a 
role in driving in vivo BMEM activation.
BMEM cells proliferate upon in vivo antigen encounter  
and do not express GC markers or generate GC structures
The rapid kinetics of the BMEM response led us to question 
whether BMEM form GCs after antigen encounter. Clonally 
expanding BMEM were tracked to define their transitional 
stages en route to differentiating into ASCs. Under steady-
state conditions, PE-BMEM displayed a GL7PNAKi-
67 CD38+ phenotype as anticipated (Fig. 3 A; Lalor et al., 
1992). As a positive control for GC markers, Peyer’s patches 
were harvested and gated on B220+IgD cells, a population 
known to be primarily GC B cells, with these cells exhibiting 
a GL7+PNA+Ki-67hiCD38 phenotype (Butcher et al., 
1982). When PE-BMEM were harvested and analyzed 3 d after 
sPE challenge, they were GL7PNAKi-67hiCD38+, indi-
cating these cells had responded to antigen because of Ki-67 
expression, yet failed to express the GC markers GL7 and 
PNA (Fig. 3 A). It was plausible that the failure of antigen-
responding BMEM to gain a GC phenotype was caused by the 
solitary use of sPE, and that the induction of a GC phenotype 
requires the presence of an adjuvant. Therefore, CpG was 
added to sPE, and 3 d later, the phenotype of the responding 
BMEM was analyzed. The addition of CpG to sPE again elic-
ited GL7PNAKi-67hiCD38+ BMEM (Fig. 3 A). It was con-
sidered possible that BMEM gain a GC phenotype later than 3 d 
after antigen encounter, so the phenotype of BMEM was ana-
lyzed at later points in time. The results indicate that PE-BMEM 
maintain a GL7PNACD38+ phenotype throughout the 
cell cycle (Fig. 3 B). These data define a proliferating state 
of BMEM occurring shortly after in vivo antigen encounter, 
rechallenge, BMEM began to proliferate, with this response 
peaking by day 4 (Fig. 2 C and Fig. S3 A). In mice analyzed 
during the BrdU chase period (days 11 and 24 after sPE rechal-
lenge), a proportion of BMEM remained BrdU+ at a percentage 
similar to that observed at the peak of the response (35.5% ± 
SEM 4.6 and 38.4% ± SEM 5.1 versus 48.9% ± SEM 5.8, re-
spectively), indicating that 71–77% of BMEM proliferation oc-
curs within the first 5 d after antigen rechallenge (Fig. 2 C and 
Fig. S3 A). A second PE-binding population was also observed 
in these experiments, with this population displaying a 
B220PE+ phenotype (Fig. S3 A). When the BrdU incorpora-
tion frequencies by the B220PE+ population in PBS versus 
sPE-immunized mice were compared, no differences were 
observed between the two groups over the 24-d kinetic 
analysis (unpublished data). This indicates that the B220PE+ 
population does not respond to sPE, and as antigen-respon-
siveness is a crucial element of adaptive memory, we excluded 
these cells from further analysis. As BrdU labeling measures 
the accumulation of proliferation over the time of the BrdU 
“pulse” period, we also analyzed BMEM expression of Ki-67 at 
various times after antigen challenge (Fig. 2 F). Ki-67 expres-
sion is an indicator of all stages of the cell cycle and provides a 
snapshot of the proliferative state of the BMEM at a given point 
in time (Gerdes et al., 1984). PE-BMEM are almost uniformly 
Ki-67, which is indicative of their quiescent state (Fig. 2 F). 
By days 3 and 4 after sPE rechallenge, 76–77% of BMEM cells 
were Ki-67+. At day 5, Ki-67 expression began to dissipate, 
and most PE-BMEM exhibited decreased Ki-67 expression on 
day 7, with this decrease more pronounced by day 11. By day 
24, PE-BMEM were once again uniform in their lack of Ki-67 
expression (Fig. 2 F). In correlating the expression pattern of 
Ki-67 by BMEM (Fig. 2 F) with the 5-d BrdU pulse followed by 
a chase period (Fig. 2 C), the results indicate that the majority 
of BMEM proliferation occurs between days 2 and 5 after sPE 
rechallenge. In addition, the presence of BrdU+ BMEM 24 d af-
ter sPE injection provides direct evidence that BMEM generate 
daughter BMEM after secondary antigen encounter.
A rapid increase in the numbers of IgG+ PE-ASCs in 
both the spleen and BM was observed 3 d after sPE rechal-
lenge (Fig. 2, B and D). This burst in ASC numbers peaked 
4 d after challenge in the spleen and 5 d in the BM, after 
which ASC numbers gradually subsided over the next 20 d 
(Fig. 2 D). Corresponding to the increase of ASCs after re-
challenge was an increase in anti-PE IgG serum titers increas-
ing 10-fold over the next 20 d (Fig. 2 E). These data show 
that ASCs are rapidly generated within 3 d after antigen re-
challenge and are present to substantial degrees in both the 
spleen and the BM. Soon thereafter, ASC numbers declined, 
indicating that short-lived ASCs are present in both organs.
(CD40), CD40, 10 µg/ml; and IL-4, 10 ng/ml. The percentage of B220intCD138+ cells derived from NF B cells (open bars) or BMEM (filled bars; H) and the 
percentage of cells proliferating as measured by dye dilution of DDAO (I) are depicted. Data presented is representative (A–G) or pooled (H and I) from 
three to five independent experiments. Purified BMEM are pooled from six to eight mice per experiment, with NF B cells isolated from one mouse per ex-
periment. Results in G–I are expressed as the mean ± SEM.
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Figure 2. BMEM cells undergo rapid self-renewal and differentiation into IgG+ PCs in response to soluble antigen. Either naive or PE-immunized 
mice were challenged with PBS, 1 µg sPE, or 1 µg sPE + 50 µg CpG and 3 d later, IgM+, and IgG+ PE-PCs from the spleen were quantified by ELISPOT  
(A and B). To measure the proliferation of BMEM, PE-immunized mice were injected with 5 µg sPE or PBS with BrdU added to the drinking water and con-
tinued for five days as shown (C). A group of immunized mice were included that were not given BrdU or sPE (C). At the indicated day after rechallenge, 
the percentage of PE-BMEM incorporating BrdU was measured by FACS (C). In parallel, IgG+ PE-PCs were quantified in sPE- and PBS-injected mice from 
both the spleen and BM by ELISpot (D). The levels of IgG+ PE-specific serum antibody titers present on the indicated days after sPE injection were com-
pared with titers present in PBS injected mice by ELISA (E). The expression levels of intracellular Ki-67 by PE-BMEM (DumpB220+PE+; pregates not shown; 
Dump, CD4+CD8+IgD+IgM+) was measured at the indicated time points after sPE injection by FACS, with representative plots depicted (F). Plots were 
stained and analyzed on the same day. To examine the impact of varying sPE dose during rechallenge, PE-immunized mice were rechallenged with 1, 10, 
100 µg sPE or PBS only, with BrdU given daily in the drinking water. After 3 d, the percentage of PE-BMEM incorporating BrdU was measured by FACS (G). 
The same experimental setup used in G was used in H, except mice were injected with PBS, 1 µg sPE, or 1 µg PE with 50 µg CpG, with BrdU incorporation 
by PE-BMEM again depicted. Three to five mice per experimental group were used per experiment. Data presented are representative of two to three inde-
pendent experiments, with A and B pooled from two independent experiments. Error bars in C–E are expressed as the mean ± SEM. AU, arbitrary units. 
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jection with LPS, CpG, or CD3 alone or CD3 and LPS or 
CpG, no proliferation was observed for either NF B cells or 
PE-BMEM (Fig. 4, A and B, and Fig. S5). These data indicate 
that both NF B cells and PE-BMEM proliferate in response to 
CD40 signals in vivo, whereas TLR agonists or activation 
of T cells with CD3 did not induce BMEM proliferation.
To determine whether BMEM differentiate into ASCs after 
signaling through CD40, PE-immunized mice were injected 
with PBS, sPE, CpG, CD40, or both CD40 and CpG. 
IgG+ PE-ASCs after agonist injection were quantified, and 
only in the sPE challenged mice was an increase in IgG+ PE-
ASC numbers observed (unpublished data). The numbers of 
BM IgG+ PE-ASCs after agonist treatment were also ana-
lyzed, with serum harvested on the day of agonist injection 
and again when analyzed 14 d later. The only treatment 
group in which an increase in numbers of BM IgG+ PE-
ASCs and serum PE-specific IgG was observed in the sPE-
treated cohort (Fig. 4, C and D).
These data indicate that TLR4 and TLR9 agonists and 
the proinflammatory cytokine storm elicited by agonistic 
CD3 treatment are incapable of activating BMEM and driv-
ing their proliferation or differentiation in vivo. Engagement 
of CD40 (either alone or coupled with TLR4 and TLR9 ag-
onists) drives both NF B cell and BMEM proliferation, but is 
incapable of mediating their differentiation into ASCs.
BMEM cells do not proliferate or differentiate into ASCs  
in vivo after immunization with an irrelevant protein 
antigen or vaccinia virus infection
The capacity of PE-BMEM to proliferate and differentiate in 
response to either immunization with NP-KLH/alum ad-
ministered with CpG or infection with vaccinia virus West-
ern Reserve strain (VACVWR) was analyzed. The levels of 
BMEM proliferation and their differentiation into ASCs were 
measured 17 d later with this time chosen to allow for the full 
development of an adaptive immune response against either 
NP-KLH or VACVWR. After immunization with VACVWR 
or NP-KLH, PE-BMEM did not incorporate any more BrdU 
(15.9% ± SEM 1.8 and 16.6% ± SEM 2.3, respectively) and 
then after injection with PBS alone (19.22% ± SEM 1.5; Fig. 
S6 C and Fig. 5 A). As anticipated, sPE induced robust PE-
BMEM cell proliferation, with the majority (73% ± SEM 2.8) 
of cells BrdU+ (Fig. S6 C and Fig. 5 A). The generation of 
IgG+ PE-ASCs was also measured by comparing the levels of 
PE+ IgG+ serum antibody titers present before and after im-
munization and by quantifying the number of IgG+ PE-ASCs 
present in the spleen and BM by ELISPOT. VACVWR and 
NP-KLH immunizations did not impact the number of IgG+ 
PE-ASCs present in either the spleen or the BM 17 d after 
immunization (Fig. 5, B and C). There was also no difference 
in the levels of IgG+ PE-specific serum antibody titers after 
VACVWR or NP-KLH immunization (Fig. 5 D). Consistent 
with these BMEM expressing a GL7PNAKi-67hiCD38+ 
phenotype.
To investigate whether antigen-activated BMEM generate 
GCs, GC structures were quantified in spleens where PE-
BMEM were either unchallenged or were responding to sPE or 
sPE + CpG by immunofluorescence (IF) microscopy. As a 
positive control for the presence of GCs, naive BALB/c were 
immunized with PE/alum and spleens were examined 10 d 
later at the height of the GC response. To ensure that PE-
BMEM in the sPE- and sPE + CpG–treated groups and the 
PE-GC B cells in the D10 PE/alum immunized groups were 
present and proliferating in these mice, FACS analysis was 
performed on half of the spleens, with BrdU incorporation 
by B220+PE+ cells analyzed (Fig. S4). Upon IF evaluation, in 
the D10 PE/alum immunized spleens, GL7+ clusters were 
observed and proximal to CD35+ follicular DCs, with these 
structures detected in 50% of the B cell follicles (Fig. 3, C 
and D). These GL7+ cell clusters were minimally present in 
the PBS-, sPE-, and sPE + CpG–treated groups (Fig. 3, C 
and D). Importantly, there was no significant increase in the 
number of GCs present in spleens where BMEM were acti-
vated by sPE or sPE + CpG in comparison to PBS controls 
(Fig. 3 D). These data, coupled with the GL7PNAKi-
67hiCD38+ phenotype displayed by BMEM after in vivo anti-
gen-dependent activation, demonstrate that GCs are not 
created by BMEM after antigen rechallenge.
Analysis of the in vivo BMEM cell response to TLR agonists, 
CD40 agonists, and bystander T cell help
The in vivo BMEM response to TLR agonists, CD40 agonists, 
and bystander T cell help was determined. PE-immunized 
mice were injected with PBS, sPE as a positive control, com-
binations of TLR agonists, agonistic CD40, and/or CD3. 
We treated mice with agonist doses at or greater than doses 
known to have an optimal biological effect in vivo (Ferran 
et al., 1990; Ahonen et al., 2004). In data where 50 µg of CpG 
was used, similar data were obtained using 100 µg (unpub-
lished data). Furthermore, the efficacy of the TLR agonists 
was confirmed by observing an induction in the expression of 
CD86 by both NF B cells and CD11c+ DCs 24 h after TLR 
agonist injection in vivo (unpublished data). PE-BMEM prolif-
eration was tracked by BrdU incorporation over a period of 
3 d (Fig. S5 A). NF B cells were included in this analysis and 
were identified as B220+IgD+ cells (Fig. S5 B). Injection with 
PBS alone elicited very low amounts of BrdU incorporation 
by both NF B cells and PE-BMEM, whereas injection with 
sPE elicited only BMEM proliferation (Figs. 4, A and B, and 
Fig. S5). It was observed that both BMEM and NF B cells pro-
liferate in response to injection with agonistic CD40 anti-
body alone or coupled with LPS or CpG, with the mean 
proliferation of both subsets as measured by BrdU incorpora-
tion between 25 and 50% (Fig. 4, A and B, Fig. S5). After in-
Each point in A, B, G, and H represents an individual mouse, with horizontal line representing the mean. Results of a Student’s t test are shown as com-
parisons between the indicated experimental groups: ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 3. BMEM cells proliferate upon in vivo antigen encounter and do not express GC markers or generate GC structures. PE-immunized 
mice were injected with PBS, 10 µg sPE, or 10 µg sPE + 50 µg CpG. 3 d later, PE-BMEM (Dump-B220+PE+; pregates not shown and Dump = 
CD4+CD8+IgD+IgM+) in each treatment group were analyzed for their expression of GL7, PNA, Ki-67, and CD38 by FACS. Included in this analysis were 
lymphocytes harvested from the Peyer’s patches of the same mice and gated on B220+IgD (PP-GC; pregates not depicted). Representative data depicted 
are histograms of indicated phenotypic marker (A). A similar experiment was performed with responding PE-BMEM examined at various time points after 
10 µg sPE rechallenge (B). To detect the presence of GCs in mice harboring antigen-responding BMEM, PE-immunized mice were rechallenged with PBS, 
sPE, or sPE + CpG. Included in the analysis were BALB/c mice that had received a primary PE/alum immunization 10 d prior. GCs in each group were quan-
tified by IF microscopy (C) and are represented as the percentage of splenic IgD+ B cell follicles harboring GL7+ foci, with 50–75 follicles counted/spleen 
(D). A and B are representative of three experiments, with three to four mice analyzed on each day. The IF experiment contained three mice analyzed from 
two independent experiments (C and D). For IF images, green represents GL7, blue represents IgD, and purple represents CD35. Bar, 100 µm. In D, each 
point represents an independent mouse, with line representing the mean. Results of an unpaired Student’s t test in D are shown as a comparison between 
indicated groups. ***, P < 0.001.
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Figure 4. Analysis of the in vivo BMEM cell response to TLR ago-
nists, CD40 agonists, and bystander T cell help. PE-immunized mice 
were injected i.p. with PBS, 10 µg sPE, 50 µg CpG, 50 µg LPS, 100 µg 
CD40, or 5 µg CD3 either alone or in combination as indicated. For A 
and B, BrdU was added to the drinking water at the time of injection and 
for the duration of the experiment. The percentage of splenic NF B cells 
and PE-BMEM incorporating BrdU was analyzed 3 d later by FACS  
(A and B, as indicated). To analyze whether CpG and CD40 either alone 
or in combination enhanced the number of PE-PCs in the BM, mice re-
ceived the indicated agonist and were sacrificed 14 d later, with the num-
ber of IgG+ PE-PCs in the BM quantified by ELISpot (C). Furthermore, 
serum was harvested on the same day as agonist injection (Day 0), as well 
as on the day of sacrifice (Day 14), with the titers of IgG+ PE-specific anti-
body titers analyzed on both days by ELISA (D). In A–C, three to four mice 
per experimental group were used per experiment. Data shown is pooled 
from three independent experiments. In A–C, each dot depicts an indi-
vidual mouse, with mean indicated by horizontal line. In D, each group 
contains seven mice, with data expressed as the mean ± SEM. AU, arbi-
trary units. D is the pooled data of two independent experiments. Results 
of an unpaired Student’s t test are shown as comparisons between the 
indicated experimental group and the PBS control group: no denotation, 
no significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
with our earlier observations (Fig. 2, D and E), sPE induced 
a substantial and significant increase in the number of IgG+ 
PE-ASCs in both the spleen and BM (Fig. 5, B and C) and 
led to an 30-fold increase in the levels of IgG+ PE-specific 
serum antibody titers (Fig. 5 D). Both cellular and humoral 
anti-VACVWR immune responses were verified to have oc-
curred by testing for the presence of IFN-+ VACVWR-
 specific CD4 and CD8 T cells in spleens harvested from 
VACVWR-infected mice, but not naive mice, and by observ-
ing for the presence of anti-VACVWR IgG serum antibodies 
only in infected mice (Fig. S6, A and B).
These data collectively demonstrate that immunization 
with NP-KLH and VACVWR infection does not induce PE-
BMEM proliferation or differentiation into ASCs. Thus, BMEM 
are unresponsive to stimuli generated during a bystander im-
mune response.
DISCUSSION
A detailed analysis of the in vivo secondary immune response 
of BMEM in response to cognate antigen versus noncognate 
inflammatory bystander signals is presented. These data show 
that BMEM respond robustly upon rechallenge with cognate 
antigen, but do not acquire the expression of GC markers or 
form GCs in response to cognate antigen. In striking contrast, 
the response of BMEM to a battery of proinflammatory signals 
is remarkably silent. It has been proposed that serological 
Figure 5. BMEM cells do not proliferate or differentiate into PCs in 
vivo after immunization with an irrelevant protein antigen or vac-
cinia virus infection. PE-immunized mice were injected i.p. with PBS,  
10 µg sPE, 2 × 106 PFU VACVWR, or 100 µg NP-KLH/alum + 50 µg CpG, as 
indicated. BrdU was added to the drinking water at the time of injection 
and for the duration of the experiment. After 17 d, the percentage of PE-
BMEM–incorporating BrdU was quantified by FACS analysis (A). On the 
same day, the numbers of IgG+ PE-PCs were quantified in both the spleen 
and BM for each treatment group by ELISpot (B and C, respectively).  
Serum was harvested 3 d before immunization and again on day 17, with 
IgG+ PE-specific serum antibody titers from both time points shown  
(D). Horizontal lines represent the mean (A–C). In A–C, three to four mice 
per experimental group were used per experiment. Data shown in 5A is 
pooled from two independent experiments, and data shown in B and C is 
representative of one of these experiments. Results in D are expressed as 
the mean ± SEM. AU, arbitrary units. Seven to eight mice were used in 
each treatment group. D is the pooled data of two independent experi-
ments. Results of an unpaired Student’s t test are shown as comparisons 
between the indicated experimental groups in A–C. ***, P < 0.001.
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mental system excluded testing whether IgM+ BMEM are re-
sponsive to bystander inflammatory signals. There is a growing 
body of evidence both in favor of and in conflict with the 
hypothesis that serological memory is sustained by the activa-
tion of BMEM by bystander inflammation. Evidence in favor 
of this theory includes in vitro observations in which human 
BMEM were shown to have increased sensitivity and to selec-
tively proliferate and differentiate into ASCs in response to 
bystander stimuli as compared with NF B cells (Bernasconi 
et al., 2002, 2003). In vivo studies in humans found that for 
single-pathogen specificities, serum antibody levels linearly 
correlated with the frequency of BMEM present in a host, in-
dicating that the ASC compartment was genealogically linked 
to and undergoing replenishment by the BMEM compartment 
(Bernasconi et al., 2002). Mouse studies also supported this 
link between the BMEM and ASC compartments as elimina-
tion of virus-specific BMEM led to a slow decay of virus-
 specific ASC numbers over time in comparison to mice still 
containing BMEM (Slifka et al., 1998). Lastly, it was observed 
that during an immune response against a single pathogen, an 
increase in both blood ASC numbers and serum antibody 
levels occurred for specificities to other pathogens (Bernasconi 
et al., 2002). This result was interpreted as evidence that host 
BMEM were recipients of antigen-independent stimuli and re-
sponded by differentiating into ASCs.
Despite these data suggesting that BMEM respond to by-
stander inflammation, more recent studies have put this hy-
pothesis under scrutiny. In particular, further attempts to 
correlate antigen-specific BMEM numbers with circulating ASCs 
in human subjects have been unsuccessful (Amanna et al., 
2007). Mouse studies where long-lived ASC numbers were 
quantified after BMEM depletion observed no decay in ASC 
numbers over time, contrary to initial reports (Ahuja et al., 
2008; DiLillo et al., 2008). Lastly, a series of studies reported 
that in mice that were administered a TLR agonist or in hu-
mans that were given a vaccine, ASC numbers and serum anti-
body levels against specificities other than the immunizing 
antigen did not increase (Di Genova et al., 2006; Amanna 
et al., 2007; Xiang et al., 2007; Richard et al., 2008).
Our studies show that the in vitro sensitivities of BMEM to 
activation are not representative of their sensitivities in vivo 
and cast doubt on the hypothesis that BMEM can be activated 
by bystander inflammation. Our in vitro studies examining 
the response profiles of murine BMEM to both antigen-depen-
dent and -independent stimuli extended prior studies using 
human (Arpin et al., 1997; Bernasconi et al., 2002) and mu-
rine (Richard et al., 2008) BMEM, as we observe that murine 
BMEM are sensitive to TLR agonists and have an enhanced 
intrinsic ability to differentiate into ASCs upon activation 
with TLR agonists, regardless of whether the BCR is en-
gaged by antigen. Given these data, and our knowledge of 
the robust response of BMEM to cognate antigen in vivo, an 
exploration of the response of BMEM to several nonspecific 
inflammatory signals in vivo demonstrated that BMEM are in 
fact unresponsive to these stimuli. The first panel of signals 
tested was derived from activated T cells and included CD154 
memory is sustained by BMEM responding to bystander inflam-
matory signals by undergoing proliferation and differentia-
tion. However, the findings of this study indicate that BMEM 
ignore these signals (TLR agonists, polyclonal T cell activa-
tion, aggressive vaccination, and acute viral infection), as they 
fail to drive BMEM proliferation or differentiation in vivo.
Despite the preponderance of studies detailing the B cell 
dynamics of the primary humoral immune response, surpris-
ingly few studies have detailed the events of the secondary 
humoral immune response. We have tracked BMEM and dem-
onstrate that cognate antigen drives the rapid clonal expan-
sion of BMEM and their terminal differentiation into ASCs, 
with these events occurring in the absence of GC formation. 
As has been widely reported, BMEM rapidly differentiate to 
ASCs upon secondary antigen encounter (Höfer et al., 2006; 
Minges Wols et al., 2007), with this ASC response first de-
tectable 3 d after antigen challenge in both the spleen and the 
BM and with the splenic ASC response an order of magni-
tude greater than that observed in the BM. This wave of 
ASCs dissipates after 11 d, and it is probable that the remain-
ing ASCs in the BM 24 d after antigen challenge have been 
culled into the long-lived PC pool (Manz et al., 1997; Höfer 
et al., 2006; Minges Wols et al., 2007). These data detail the 
activation of BMEM and define their proliferation as occurring 
between days 2 and 5 after antigen encounter. Proliferating 
BMEM occupy a transitional state defined as antigen-binding 
B220+CD38+Ki-67+GL7PNA before generating quies-
cent daughter BMEM and/or differentiating into ASCs. This 
blasting state is unique because of the presence of high levels 
of CD38 expression by proliferating cells; CD38 is a pheno-
typic marker previously used to denote quiescent NF B cells 
and BMEM and is lost upon B cell activation and entry into the 
GC (Oliver et al., 1997). Our finding that BMEM cells do not 
form or enter a GC reaction during their differentiation and 
expansion is consistent with classical studies indicating that 
BMEM might not undergo further SHM and isotype switching 
upon rechallenge with antigen (Askonas et al., 1970; Okumura 
et al., 1976; Siekevitz et al., 1987). In these studies, limiting 
numbers of hapten-specific “parental” BMEM were adoptively 
transferred together with carrier-primed T cells into lightly 
irradiated hosts, followed by immunization of the hosts 
with soluble hapten-carrier antigen. Upon analyzing the 
isotype distribution and SHM exhibited by the parental 
BMEM and their progeny generated in response to cognate 
antigen, no change in diversity in either measure was ob-
served. Our data showing that BMEM neither gain GC mark-
ers nor seed GCs are in concordance with these studies. It 
is apparent that BMEM, at least in these studies and in our 
presented data, are not instructed to enhance the affinity or 
isotype distribution of their antigen receptors during sec-
ondary antigen encounter.
Our data indicate that quiescent IgG+ BMEM are not acti-
vated by TLR agonists or bystander T cell help, and thus do 
not undergo self-renewal events or differentiate into ASCs in 
an antigen-independent manner. We should note that our 
analysis was limited to IgG+ PE-BMEM and that our experi-
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process, with BMEM not requiring an extrinsic signal to main-
tain serological memory such as those tested herein.
MATERIALS AND METHODS
Mice and immunizations. These studies were approved by the Institu-
tional Animal Care and Use Committee of Dartmouth College (Lebanon, 
NH). BALB/c mice were purchased from the National Cancer Institute. 
RAG/ mice were purchased from The Jackson Laboratory. C1-cre mice 
crossed with Rosa26-EYFP mice have been previously described and were 
provided by K. Rajewsky (Harvard Medical School, Boston MA) and 
S. Casola (Fondazione Italiana per la Ricerca sul Cancro Institute of Molecular 
Oncology Foundation, Milan, Italy;  Casola et al., 2006). All animals were 
maintained in a pathogen-free facility at Dartmouth Medical School. For 
primary immunizations, 10 µg of R-PE (Cyanotech) or 100 µg of NP28-
KLH (Biosearch Technologies) adsorbed to prepared alum was injected i.p. 
in a volume of 200 µl. For secondary challenge, 10 µg of PE (unless indicated 
otherwise) in PBS in a volume of 200 µl was injected i.p. For VACVWR in-
fections, virus was propagated and titered on the 143B cell line as previously 
described (Fuse et al., 2008), with 2 × 106 PFU injected i.p. For BrdU treat-
ment, 0.8 mg/ml was added to the drinking water and changed daily except 
in Fig. 5 where BrdU was changed every other day.
Cell preparation. Single-cell suspensions of lymphocytes were prepared as 
previously described (Benson et al., 2008). For enrichment of splenocytes 
for BMEM before phenotyping and BrdU analysis, CD4+, CD8+, IgD+, and 
IgM+ cells were removed by negative depletion using a mix of biotinylated 
antibodies. Cells were removed using the EasySep Biotin Selection Kit for 
Mouse Cells (StemCell Technologies). For enrichment of BMEM before cell 
sorting, IgD+ and IgM+ cells were first removed, and then CD43+ cells 
were removed in a two-step process using the EasySep Mouse B Cell En-
richment Kit.
Cell culture/reagents. B cells were cultured in RPMI media supple-
mented with 10% FBS (Atlanta Biologicals), Hepes, 50 µM -ME, and peni-
cillin/streptomycin/l-Glutamine. Sorted B cells were cultured in 96-well 
round-bottomed plates with 10,000–15,000 cells/well and were cultured at 
37°C. For in vitro VACVWR CD4 and CD8 recall, BALB/c splenocytes 
were infected for 2 h with a 10:1 ratio of virus to cells. Infected cells were 
then plated in a round-bottom 96-well plate with 5 × 106 splenocytes har-
vested from either D17 VACVWR-infected or noninfected mice added and 
cultured for 6 h in the presence of 10 µg brefeldin-A and 10 U/ml IL-2. In-
tracellular staining of IFN- was performed as previously described (Fuse 
et al., 2008). The following reagents and vendors were used in this study: 
CpG-ODN1826 (5-TCCATGACGTTCCTGACGTT-3) with phos-
phorothioate bases (Eurogentec S.A.), LPS 055:B5, BrdU (Sigma-Aldrich), 
Pam4CSK4, HKLM, poly(I:C), ST-FLA, and FSL1 (Invivogen), S-27609 
(3M Pharmaceuticals), IL-4 (Peprotech), CD40 clone FGK45, and CD3 
clone 145 2C11 antibodies (Klaus Lube; BioExpress).
Flow cytometry. Antibodies against the following antigens were used: 
B220 (clone 6B2), IgG1 (clone A85-1), IgD clone (11-26c), IgM (clone 11–
41), CD4 (clone GK1.5), CD8 (clone 2.43), IFN- (clone XMG1.2), CD43 
(clone 1B11), CD38 (clone 90), CD23 (clone B3B4), CD80 (clone 1610-
A1), Ki-67 (clone B56), CD138 (clone 281–2), BrdU (clone PRB-1), CD35 
(clone 8C12), GL7, and PNA. NIP-PE and PE-binding cells were detected 
by staining with NIP20-PE (generated in-house) or with 2 µg/ml PE. For 
CFSE or DDAO dye dilution, cells were labeled with 5 µM CFSE or 10 µM 
DDAO in RPMI at 37°C for 10 min (Invitrogen). Intracellular BrdU (BD) 
and Ki-67 (eBioscience) staining was performed according to the manufac-
turers recommendations. Flow cytometry was performed on a refurbished 
FACSCAN running CellQuest software (BD), with data analysis performed 
using FlowJo (Tree Star, Inc.). Cell sorts were performed on a FACSAria 
(BD; Flow Cytometry Facility at Dartmouth Medical School).
expression by these cells, as well as proinflammatory cyto-
kines either alone or together with TLR agonists. We first 
analyzed the impact of agonistic CD40 antibodies on BMEM 
proliferation and differentiation. The injection of mice with 
CD40 alone or with TLR4 or TLR9 agonists elicited sub-
stantial levels of BMEM and NF B cell proliferation. Despite 
this proliferation, these BMEM did not differentiate into ASCs. 
These data are in agreement with our in vitro observations, 
where CD40 induced the proliferation of, yet failed to dif-
ferentiate, poly-BMEM into ASCs. These studies also extend 
previous in vitro studies where CD40 signaling triggered hu-
man BMEM proliferation, but impeded their differentiation 
into ASCs (Arpin et al., 1995). Using a second approach, we 
activated T cells in vivo through the injection of agonistic 
CD3 antibodies, with this treatment given either alone 
or with TLR agonists. Injection of this antibody is known 
to elicit rapid and transient activation of T cells, which re-
lease a proinflammatory cytokine storm that includes IL-2, 
IFN-, and TNF (Ferran et al., 1990; Scott et al., 1990). 
These stimuli did not induce either BMEM proliferation 
or differentiation.
It is highly likely that the in vivo response of BMEM to 
overt antibody-mediated CD40 signaling does not represent 
the hypothetical situation where BMEM and activated T cells 
transiently engage in a CD40/CD40L synapse independent 
of an antigen bridge. As we found no BMEM proliferation 
upon vaccination with an irrelevant thymus-dependent anti-
gen or infection with vaccinia virus (a situation generating 
large numbers of activated CD4 T cells expression CD40L), 
it is probable that this interaction does not occur and is thus 
not a mechanism for propagating BMEM renewal. Instead, this 
data should be interpreted as in vivo proof that CD40 signal-
ing drives BMEM proliferation but blocks their differentiation 
into ASCs, indicating that differentiation occurs upon cessa-
tion of CD40 signaling.
Immunization with NP-KLH, along with alum and CpG, 
and infection with vaccinia virus results in the acute induction 
of both innate and adaptive immunity. BMEM ignored the 
stimuli associated with these responses and neither proliferated 
nor differentiated into ASCs during the multi-week period in 
which these immune responses were occurring. In summary, 
inflammatory signals associated with TLR signaling, T cell ac-
tivation, and adaptive immune responses are incapable of driv-
ing BMEM proliferation or differentiation into ASCs.
The possibility remains that BMEM and long-lived PCs 
might survive for the lifetime of the host, with these popula-
tions not requiring self-renewal or replenishment and with 
serological memory not requiring maintenance. However, 
this hypothesis requires that BMEM and PCs survive for perpe-
tuity, and this quality appears unrealistic. From our presented 
work, we show that BMEM do not clonally expand or differ-
entiate in response to bystander inflammatory signals. It is 
possible that there are other signals capable of inducing in 
vivo BMEM expansion and differentiation that are not included 
in this analysis. Alternatively, the maintenance of serological 
memory may occur via a stochastic rather than an induced 
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